50results about "Phosphorus-oxygen lyases" patented technology

Provided herein are methods for producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

The invention provides a pseudomonas aeruginosa engineering bacterium which is based on a PAO1 wild type strain, and two of the following genes, namely cyaA and cyaB, are knocked out from a genome at the same time. According to the pseudomonas aeruginosa engineering bacterium, the cyaA gene and the cyaB gene are knocked out at the same time, and the yield of rhamnolipid is remarkably increased on the premise that existing PAO1 fermentation process parameters and processes are not changed. The yield cannot be increased when the cyaA or the cyaB is singly knocked out, and the synergistic effect of double-gene knockout is proved.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

The present disclosure describes compositions and methods of treating solid tumors using chimeric antigen receptor (CAR) T cell (CAR-T) therapy and / or antibodies targeting uanylate Cyclase 2C (GCC. GUCY2C). The compositions include CAR comprising an extracellular domain that binds GCC. Further disclosed are methods of using modified T ceils expressing a CAR that binds GCC for treating different types of carters.

Provided is a fusion protein. The fusion protein simultaneously blocks a calcitonin gene-related peptide (CGRP) pathway and a pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, wherein the fusion protein comprises at least one single-domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein can simultaneously block the CGRP and PACAP pathways, thereby improving the response rate of a drug for treatment of migraine.

Provided are a method for producing a target molecule on the basis of a condensation-segregation technique, a recombinant strain and the use thereof. By means of regulating the formation of biological condensates, high-concentration enrichment of target molecules at the cell end is achieved. By means of this step, highly-enriched target molecules are obtained and can be further accumulated by means of cell division. Compared with traditional methods, the method not only effectively improves the concentration of target molecules in a specific region within cells, but also realizes further accumulation of the enriched molecules by means of the mechanism of cell division.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

This disclosure relates to methods for increasing plant immunity or resistance to plant pathogens or pests, or inhibiting plant pathogens or pests, by supplying antimicrobial or antifungal oligopeptides. Antimicrobial or antifungal oligopeptides and nucleic acids encoding said oligopeptides are also provided herein. Compositions, kits, and cells comprising antimicrobial or antifungal oligopeptides are also provided.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

The invention discloses an application of a soybean RuBisCO activating enzyme family gene GmRCA11 in improvement of soybean quality. The nucleotide sequence of the soybean GmRCA11 protein coding gene GmRCA11 is shown as SEQ ID NO. 1, and the nucleotide sequence of the soybean GmRCA11 protein coding gene Genetic transformation is carried out on the PBA002-GmRCA11 overexpression vector in soybeans, and it is found that compared with a receptor Jack, the protein content in grains of an overexpression material is remarkably increased. Therefore, the soybean GmRCA11 protein coding gene GmRCA11 disclosed by the invention can be applied to the aspect of improving the soybean protein through genetic engineering.

Disclosed herein are methods that provide optimal conditions for site-specific digestion and mapping of the sequence of RNA polynucleotides using T2 family endoribonucleases, such as RNase MCI and Cusativin.

Provided herein are methods of preparing peptides from inclusion bodies by linking two or more oligopeptides to an insoluble carrier polypeptide (e.g., leopard frog enzyme or TAF12), wherein the oligopeptides are released from the insoluble carrier protein by sequence-specific chemical cleavage of the peptide linkages using an acid such as acetic acid. Also provided herein are leopard frogase variants having improved properties.

The present disclosure relates to methods of increasing plant immunity or resistance to plant pathogens or pests in a plant, or inhibiting a plant pathogen or pest by providing an antimicrobial or antifungal oligopeptide. Also provided herein are antimicrobial or antifungal oligopeptides, and nucleic acids encoding said oligopeptides. Also provided herein are compositions, kits and cells comprising antimicrobial or antifungal oligopeptides.

Disclosed are viral vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian guanylate cyclase proteins. Also disclosed are methods for their use in preventing, treating, and / or ameliorating at least one or more symptoms of a disease, disorder, abnormal condition, or dysfunction resulting at least in part from a guanylate cyclase deficiency in vivo. In particular embodiments, the use of recombinant adeno-associated viral (rAAV) vectors to treat or ameliorate symptoms of Leber's congenital amaurosis, as well as other conditions caused by an absence or reduction in the expression of a functional retinal-specific guanylate cyclase 1 (retGC1).

This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.

In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.

Disclosed herein are methods that provide optimal conditions for site-specific digestion and mapping of the sequence of RNA polynucleotides using T2 family endoribonucleases, such as RNase MC1 and Cusativin.

Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.

Compositions comprising a modified adenovirus AD5.F35 which includes coding sequence of soluble GUCY2C extracellular domain sequences are disclosed. Compositions comprising a Listeria monocytogenes vector which includes coding sequence of soluble GUCY2C extracellular domain sequences are disclosed. Methods of treating individuals diagnosed with cancer / tumors expressing GUCY2C methods of preventing micro-metastasis are disclosed.

Provided is a GUCY2C T cell antigen coupler (TAC) polypeptide having (i) an antigen binding domain (e.g., a nanobody) that binds GUCY2C, (ii) an antigen binding domain that binds a protein associated with the TCR complex, and (iii) a T cell receptor signaling domain polypeptide.

Methods of reducing serum low density lipoprotein (LDL) levels in a subject are disclosed. The methods comprise inhibiting the expression or function of adenylate cyclase in the subject, where the inhibiting comprises administering to the subject an inhibitory nucleic acid molecule, such as siRNA.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

Increased space-time yield, carbon conversion efficiency, and carbon substrate flexibility in fine chemical production. The present inventors have found that increasing cAMP levels and / or manipulating the PTS system can have a surprising positive effect on the space-time yield, carbon conversion efficiency, and carbon substrate flexibility of fine chemical production in the host organism. This was achieved by deregulating adenylate cyclase cyaa through deletion of the C-terminal regulatory region, which leads to increased cAMP levels, or by deleting the Crr protein activity that regulates the carbohydrate utilization system (carbohydrate repression resistance). Both resulted in increased production of 2-fucosyllactose and 6-sialyllactose (human milk oligosaccharides), enhancing carbohydrate utilization.

A protein according to one embodiment of the present invention has a photoactivated adenylyl cyclase activity, and consists of the amino acid sequence of SEQ ID No. 1 with 1-18 amino acid residues deleted from the C-terminus, or an amino acid sequence having 90% or more sequence identity therewith. According to the present invention, a novel photoactivated adenylyl cyclase having a higher photoactivation efficiency compared to a wild-type OaPAC protein can be provided.

The invention provides a genetically engineered bacterium for synthesizing monoterpene and a construction method and application thereof, and relates to the field of bioengineering, in particular to a gene combination, an expression vector, a host and application thereof. According to the engineering bacteria provided by the invention, Pseudomonasputida KT2440 which can tolerate various monoterpenes is taken as a chassis cell, endonuclease coding genes endA and endX are knocked out, and a heterologous fragrant folic acid synthesis module is introduced. On the basis, key rate-limiting enzyme gene modules of different biological sources are screened to systematically strengthen an endogenous MEP metabolic pathway. After metabolism enhancement, the engineering strain successfully realizes heterologous biosynthesis of the aromatic folic acid, and the yield of the engineering strain is greatly improved compared with that of an original strain. According to the method, the yield of the aromatic folic acid is increased by systematically optimizing the MEP approach for the first time, and an optimized scheme is provided for producing the monoterpenoids by a microbiological method. The construction method of the recombinant pseudomonas putida is efficient, simple and high in operability.

An immune-cell-targeting antibody or a functional fragment thereof, and an application thereof. The antibody or the functional fragment thereof targets and identifies a Triokinase / FMN cyclase C-terminus fragment sequence. The antibody can be directly used for tagging and identifying immune cells. After the antibody and an antigen polypeptide thereof combine to form a self-assembled complex, the immune cell identification effect thereof is significantly improved, and in related applications can exhibit a decreased lower detection limit, thereby greatly improving identification capabilities and detection sensitivity for various immune cells. Moreover, a probe obtained on the basis of the antibody can likewise carry various modification groups and reporter groups, and can thus be used in approaches to different application scenarios, such as flow cytometry, immunofluorescence imaging, immunoassays, detection chips, etc., and has flexible and broad applicability and scope of application.

Provided herein are methods of producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

In embodiments the invention relates to means and methods for the treatment of Parkinson's disease. In some embodiments the means and methods involve a GUCY2C agonist. The invention also relates to test systems and cells that are suited to identify new candidate compounds for the treatment of Parkinson's disease.